このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

腎障害患者の尿管開通性判定の補助としてのインジゴチンジスルホン酸ナトリウム注射剤、USP

2026年11月4日 更新者:Prove pharm

尿管開存性の判定の補助として使用した場合の Bludigo™ (インジゴチンジスルホン酸ナトリウム注射剤、USP) 0.8% の 2 回投与の有効性と安全性に対する腎障害の影響を調査するための非盲検ランダム化並行グループ研究

This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.

調査の概要

詳細な説明

An estimated glomerular filtration rate (eGFR) at baseline will be determined using the Modification of Diet in Renal Disease (MDRD) and standardized by using individual's body surface area as described in the FDA's Renal Impairment guidance. Qualified subjects/patients will be stratified into 4 cohorts based on their eGFR at baseline: patients with normal renal function (eGFR ≥ 90 mL/min), patients with mild (eGFR 60-89 mL/min), moderate (eGFR 30-59 mL/min) and severe (eGFR 15-29 mL/min) renal impairment.

Up to ten study centers in the United States will enroll up to approximately 12 subjects per cohort (48 subjects in total) scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure, age 18 to 85 years inclusive covering the full renal function range from normal, mild, moderate, and severe renal impairment. For each subject/patient the study will consist of a screening period (Day -30 to Day -2), a baseline evaluation (Day -1 to Day 1) and a single treatment period (Day 1) with an onsite observation period of 24 hours post-dose. After signing the informed consent, review of inclusion and exclusion criteria will be performed, the collection of concomitant medications, medical history, physical examination, baseline laboratory testing, 12-lead ECG, and vital sign measurements will be completed during the screening visit.

On the day of surgery (Day 1) subjects will be evaluated for eligibility for randomization. Eligible subjects will be stratified by cohort and randomized in a 1:1 ratio to receive a dose of either Bludigo™ high dose (5.0 mL) or Bludigo™ low dose (2.5 mL). All randomized subjects will serve as his/her own control (i.e., intra-patient controlled) for efficacy by receiving a dose of normal saline prior to receiving the randomized Bludigo™ dose. The surgeon will be blinded to the Bludigo™ dose a subject receives. Time of injection of saline and Bludigo™ will be captured.

All treated subjects will have a follow-up visit 7 to 30 days (± 2 days) after the procedure. A final telephone follow-up call will occur on Day 30 (± 2 days) in subjects who have the follow-up visit before Day 28.

Safety assessments will include monitoring of AEs during and post the procedure, clinical laboratory tests, 12-Lead ECG, and vital sign measurements.

研究の種類

介入

入学 (推定)

48

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • New York
      • Albany、New York、アメリカ、12008
        • 募集
        • Albany Medical Center
        • コンタクト:
          • Mark D White, MD
          • 電話番号:518-262-8579
          • メール:whitem@amc.edu

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Subjects between ≥ 18 and ≤ 85 years old
  • Subjects who signed a written IRB approved, informed consent form
  • Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure.
  • An estimated glomerular filtration rate (eGFR) at baseline will be determined using the Modification of Diet in Renal Disease formula (MDRD) and standardized by using individual's body surface area.

Subject's renal function will be defined based on the following criteria:

  • Normal subjects: eGFR of ≥90 mL/min
  • Mild renal impairment: eGFR 60 to 89 mL/min
  • Moderate renal impairment: eGFR 30 to 59 mL/min
  • Severe renal impairment: eGFR 15 to 29 mL/min

Subjects with normal renal function that are judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests performed at the Screening Visit and/or prior to administration of study drug.

Patients with renal impairment (mild, moderate, or severe) who have a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in renal function) renal insufficiency meeting criteria at the Screening Visit

Exclusion Criteria:

  • Subjects with eGFR <15 mL/min or expected need for dialysis in the near future, or having only 1 kidney
  • Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes
  • Known history of drug or alcohol abuse within 6 months prior to the time of screening visit
  • Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g., major systemic diseases)
  • Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures
  • Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
  • Subjects with life expectancy < 6 months
  • Requirement for concomitant treatment that could bias primary evaluation.
  • Subjects who are pregnant or breast-feeding

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Saline

48 subjects treated with 5 ml of saline then crossover to treatment arm

Placebo

実験的:High Dose

24 subjects randomly treated with 5 mL of drug

Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

他の名前:
  • ブルーディゴ

Placebo

実験的:Low Dose

24 subjects randomly treated with 2.5 mL of drug

Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

他の名前:
  • ブルーディゴ

Placebo

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Paired sample difference (Bludigo - Saline) in urine jet conspicuity score.
時間枠:10 to 15 minutes post study drug administration

Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:

  1. = No jet observed
  2. = Weak jet, little color contrast
  3. = Color contrast or significant jet flow
  4. = Strong jet flow with good color contrast
  5. = Strong jet flow with striking contrast in color

Paired sample difference (Bludigo™-Saline) in conspicuity score (PSDCS). PSDCS will be calculated for each ureter (left or right) for each subject from each reviewer.

10 to 15 minutes post study drug administration
Responders to Bludigo
時間枠:10 to 15 minutes post study drug administration

Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:

  1. = No jet observed
  2. = Weak jet, little color contrast
  3. = Color contrast or significant jet flow
  4. = Strong jet flow with good color contrast
  5. = Strong jet flow with striking contrast in color

A subject is considered a responder to Bludigo™ if there is >=1 point improvement in the conspicuity score following the Bludigo™- treatment vs the saline treatment and the conspicuity score for the Bludigo™ treatment must be (3, 4, or 5). The responder criteria will be assessed separately for each ureter (left or right) from each reviewer.

10 to 15 minutes post study drug administration

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of adverse events and serious adverse events.
時間枠:30 days post study drug administration

Percentage of patients in each treatment group who experience an adverse event post treatment

30 days post study drug administration
Changes in clinical safety laboratory values
時間枠:30 days post study drug administration

Proportion of subjects with clinically important changes in clinical safety laboratory tests after treatment

30 days post study drug administration
Changes in vital signs post treatment
時間枠:30 days post study drug administration

Proportion of subjects with clinically important changes in vital signs after treatment

30 days post study drug administration
Changes in ECG post treatment
時間枠:30 days post study drug administration

Proportion of subjects with clinically important changes in ECGs after treatment

30 days post study drug administration
Changes in blood pressure by dose group and Renal Impairment Cohort
時間枠:30 days post study drug administration

Comparison of post treatment changes in blood pressure by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment)

30 days post study drug administration
Changes in heart rate by dose group and Renal Impairment Cohort
時間枠:30 days post study drug administration

Comparison of post treatment changes in heart rate by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment)

30 days post study drug administration
Changes in pulse oximetry by dose group and Renal Impairment Cohort
時間枠:30 days post study drug administration

Comparison of post treatment changes in pulse oximetry by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment)

30 days post study drug administration
Time to visualization
時間枠:10 to 15 minutes post study drug administration

To describe the time to visualization (TTV) of blue color in the ureteral jets flow following Bludigo™ treatment

10 to 15 minutes post study drug administration
Physician Satisfaction
時間枠:10 to 15 minutes post study drug administration

To determine physicians' overall satisfaction with the Bludigo™ treatment by assessing the proportion of surgeons who agree using the 5-point Physician Satisfaction Agreement Scale (PSAS) with the statement:

"Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of Bludigo™."

  1. = Strongly Agree
  2. = Agree
  3. = Neither Agree nor Disagree
  4. = Disagree
  5. = Strongly Disagree A surgeon's evaluation is considered satisfactory if the rating is either a 1 (strongly agree) or 2 (agree).
10 to 15 minutes post study drug administration

その他の成果指標

結果測定
メジャーの説明
時間枠
Difference between the Bludigo™ high dose vs Bludigo™ low dose in urine jet conspicuity score
時間枠:10 to 15 minutes post study drug administration

An exploratory comparison will be performed to assess the difference between the Bludigo™ high dose vs Bludigo™ low dose in urine jet conspicuity score.

The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:

  1. = No jet observed
  2. = Weak jet, little color contrast
  3. = Color contrast or significant jet flow
  4. = Strong jet flow with good color contrast
  5. = Strong jet flow with striking contrast in color
10 to 15 minutes post study drug administration
Impact of renal impairment on renal elimination of Bludigo™
時間枠:12 hours post study drug administration

An exploratory comparison will be performed to assess the impact of renal impairment on renal elimination of Bludigo™.

12 hours post study drug administration
Urinary excretion of Bludigo in patients with and without renal impairment
時間枠:12 hours post study drug administration

An exploratory assessments of the amount of Bludigo excreted in urine in patients with and without renal impairment.

12 hours post study drug administration

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Michelle Boytim, Ph.D.、Provepharm SAS

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年12月20日

一次修了 (推定)

2026年12月30日

研究の完了 (推定)

2026年12月31日

試験登録日

最初に提出

2023年10月6日

QC基準を満たした最初の提出物

2023年10月12日

最初の投稿 (実際)

2023年10月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PVP-22IC05

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する